相关实验视频

Updated: Jul 10, 2025

An Engineered Split-TET2 Enzyme for Chemical-inducible DNA Hydroxymethylation and Epigenetic Remodeling

An Engineered Split-TET2 Enzyme for Chemical-inducible DNA Hydroxymethylation and Epigenetic Remodeling

Published on: December 18, 2017

响应pH的DNA四面体/甲甲药物输送系统用于治疗类风湿性关节炎

Yi Jin^1,2, Xingyu Ge³, Yinjin Xu¹

¹Department of Rheumatology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226000, China.

Journal of functional biomaterials

|November 24, 2023

概括

这项研究开发了一种新型的DNA四面体药物输送系统,载有甲醇,用于治疗类风湿性关节炎 (RA). 该系统有效地向巨细胞和炎症关节,减少炎症并改善小鼠的疾病状况.

科学领域:

生物医学工程生物医学工程
药物输送系统药物输送系统
免疫学免疫学免疫学

背景情况:

类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,导致关节炎症和组织损伤.
巨细胞激活释放TNF-α和IL-1β等炎症性细胞因子,加剧RA.
针对组织损伤和炎症对有效的RA治疗至关重要.

研究的目的:

开发和评估针对巨细胞的,对pH值敏感的DNA四面体 (TET) 药物输送系统,用于RA治疗.
在RA的临床前模型中研究甲基酸加载TET (MTX-TET) 的治疗潜力.

主要方法:

构建了一个DNA四面体 (TET) 药物载体,装载着甲状腺酸盐 (MTX).
用氨酸 (HA) 修改的TET用于细胞向.
在实验室使用巨细胞检测和体内使用原诱导关节炎 (CIA) 鼠标模型评估MTX-TET的疗效.

主要成果:

成功准备了MTX装载的TET,这些TET向巨细胞并诱导M1极化.
在CIA小鼠中,MTX-TET治疗显著缓解了脚发红和胀.
组织化学分析证实了减少突炎,关节胀和炎症因素,具有良好的安全性.

结论:

在RA模型中,MTX-TET系统证明了炎症关节和巨细胞的有效向.
这种新型药物输送系统显示了对RA的显著治疗益处,减少炎症和改善关节健康.
MTX-TET为类风湿性关节炎的临床治疗提供了一个有前途的新策略.

关键词:

DNA是四面体的四面体.类风湿性关节炎类风湿性关节炎类风湿性关节炎巨细胞是一个巨细胞.甲基特雷克萨酸盐的使用方法

更多相关视频

Methionine Functionalized Biocompatible Block Copolymers for Targeted Plasmid DNA Delivery

Methionine Functionalized Biocompatible Block Copolymers for Targeted Plasmid DNA Delivery

Published on: August 6, 2019

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...